This is in accordance with mutations of NRAS that sensitize towards MEK inhibitors in different kind of tissues including lung cancer, neuroblastoma, melanoma and T-cell lymphoma [12, 13, 15]. Here, MAP2K7 is linked to T-cell non-Hodgkin lymphoma.